At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMMX Immix Biopharma, Inc.
Post-Mkt 04-29 17:42:25 EDT
8.63
+0.03
+0.35%
盘后8.65
+0.02+0.23%
16:47 EDT
High8.81Low8.30Vol595.24K
Open8.62D1 Closing8.60Amplitude5.93%
Mkt Cap457.00MTradable Cap357.62MTotal Shares52.96M
T/O5.09MT/O Rate1.44%Tradable Shares41.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Immix Biopharma to participate in Jefferies Global Healthcare Conference, hosts investor meetings
Reuters  ·  04-09
Immix Biopharma to participate in Jefferies Global Healthcare Conference, hosts investor meetings
Immix Biopharma announces annual shareholder meeting
Reuters  ·  04-07
Immix Biopharma announces annual shareholder meeting
Infinimmune: Under Agreement, Merck Will Have Exclusive Right to Develop and Commercialize Antibody Candidates
THOMSON REUTERS  ·  03-31
Infinimmune: Under Agreement, Merck Will Have Exclusive Right to Develop and Commercialize Antibody Candidates
Immix Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones  ·  03-31
Immix Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
TIPRANKS  ·  03-30
Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
Immix Biopharma completes enrollment in NEXICART-2 AL amyloidosis BLA-enabling trial
Reuters  ·  03-30
Immix Biopharma completes enrollment in NEXICART-2 AL amyloidosis BLA-enabling trial
Immix Biopharma Announces Enrollment Completion of Bla-Enabling Relapsed/Refractory Al Amyloidosis Trial Nexicart-2, and Upcoming Milestones
THOMSON REUTERS  ·  03-30
Immix Biopharma Announces Enrollment Completion of Bla-Enabling Relapsed/Refractory Al Amyloidosis Trial Nexicart-2, and Upcoming Milestones
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-27
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $15 From $12
THOMSON REUTERS  ·  03-27
Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $15 From $12
U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings
Reuters  ·  03-27
U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings
Immix Biopharma, Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-26
Immix Biopharma, Inc reports results for the quarter ended December 31 - Earnings Summary
Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate
Benzinga  ·  03-26
Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate
Immix Biopharma Inc - Enters Amendment No. 1 to Atm Offering Agreement on March 25, 2026 - SEC Filing
THOMSON REUTERS  ·  03-26
Immix Biopharma Inc - Enters Amendment No. 1 to Atm Offering Agreement on March 25, 2026 - SEC Filing
Immix Biopharma amends at-the-market equity distribution agreement; offering size holds at $100 million
Reuters  ·  03-26
Immix Biopharma amends at-the-market equity distribution agreement; offering size holds at $100 million
Immix Biopharma FY2025 operating loss widens 43.73% to $29.4 million; revenue is not available
Reuters  ·  03-26
Immix Biopharma FY2025 operating loss widens 43.73% to $29.4 million; revenue is not available
Immix Biopharma Initiated at Overweight by Morgan Stanley
Dow Jones  ·  03-25
Immix Biopharma Initiated at Overweight by Morgan Stanley
Immix Biopharma initiated with an Overweight at Morgan Stanley
TIPRANKS  ·  03-25
Immix Biopharma initiated with an Overweight at Morgan Stanley
Immix Biopharma, Inc expected to post a loss of 16 cents a share - Earnings Preview
Reuters  ·  03-21
Immix Biopharma, Inc expected to post a loss of 16 cents a share - Earnings Preview
Immix Biopharma Initiated at Market Outperform by Citizens
Dow Jones  ·  03-09
Immix Biopharma Initiated at Market Outperform by Citizens
Immix Biopharma initiated with an Outperform at Citizens
TIPRANKS  ·  03-09
Immix Biopharma initiated with an Outperform at Citizens
No data available

Introduction

Company Name.
Immix Biopharma, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Issue price:
--